Welcome to the News You Might Have Missed, a weekly roundup of news items to help you catch up and stay informed.
It was a busy week with lots of news, have a look and see you next week for another update.
Johns Hopkins Study Shows Psilocybin Effective for a Year
“Our findings add to evidence that, under carefully controlled conditions, this is a promising therapeutic approach that can lead to significant and durable improvements in depression,” says Natalie Gukasyan, M.D.
Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism
Will Rascan, CEO of NOVA. “The clear positive data is critical as we prepare to submit our clinical trial application to Health Canada for a Phase 2A study evaluating psilocybin microdose therapy for fragile X syndrome.”
NeonMind to Open its Inaugural Specialty Mental Health Clinic in
- Mississauga facility expected to begin treatment services in the Second Half of 2022
- First location selected as part of a nationwide buildout of NeonMind-branded clinics offering interventional psychiatry treatments
Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules
Company reports positive clinical data assessing cardiovascular risk for patent-pending microdose compound.
PharmaTher Receives U.S. Patent For Ketamine
The company announced that it’s been granted a new patent for the combination of FDA-approved ketamine and PharmaTher’s proprietary betaine anhydrous (“KETABET™”).
Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access Program
Optimi’s CEO, Bill Ciprick, says the SAP is already having a positive impact on patients in need and will provide the Company with the right avenue to develop and supply the demand for natural psilocybin.